← All trials
NCT07110038
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2025
- Primary completion
- May 31, 2029
- Completion date
- Nov 30, 2030
- First posted
- Aug 7, 2025
- Last posted
- Aug 7, 2025
- Enrollment
- 25
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- IKF Klinische Krebsforschung GmbH am Krankenhaus NordwestLead sponsor
- AstellasCollaborator
- Merck KGaACollaborator
- Institut für Klinische Krebsforschung IKF GmbHOfficial
- University of TuebingenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.